DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today Inspire scientists and collaborators are presenting additional data from TIGER-1, the Company’s first Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis, at the European Cystic Fibrosis Society annual meeting June 10 - 13, 2009 in Brest, France.
